v3.19.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss $ 1,975 $ (8,519) $ (6,415) $ (16,608)
Loss (income) from discontinuing operations (6,778) 5,082 (722) 13,462
Loss from continuing operations (4,803) (3,437) (7,137) (3,146)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation     42 120
Amortization     328 379
Stock-based compensation     226 403
Change in fair value of warrant liability, acquisition note payable and other derivatives     (331) (2,926)
Change in fair value of siParadigm Earn-Out     982 0
Amortization of discount of debt and debt issuance costs     470 57
Interest added to Convertible Note     268 0
Modification of 2017 Debt warrants     0 83
Impairment of goodwill 2,873 0 2,873 0
Loss in equity-method investment     0 4
Loss on extinguishment of debt     256 0
Changes in:        
Accounts receivable     (36) 521
Other current assets     (555) (420)
Operating lease right-of-use assets     123 0
Other non-current assets     (57) 5
Accounts payable, accrued expenses and deferred revenue     1,721 742
Obligations under operating leases     (156) 0
Deferred rent payable and other     0 (34)
Net cash used in operating activities, continuing operations     (983) (4,212)
Net cash used in operating activities, discontinuing operations     (4,556) (7,227)
Net cash used in operating activities     (5,539) (11,439)
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of fixed assets     (71) (17)
Net cash provided by (used in) investing activities, continuing operations     3,015 (17)
Net cash provided by (used in) investing activities, discontinuing operations     (562) 737
Net cash provided by investing activities     2,453 720
CASH FLOWS FROM FINANCING ACTIVITIES        
Principal payments on obligations under finance leases     (14)  
Principal payments on obligations under finance leases       (39)
Proceeds from offerings of common stock, net of certain offering costs     5,412 0
Proceeds from Convertible Note     0 2,500
Advance from NovellusDx, Ltd.     0 1,500
Net cash provided by financing activities, continuing operations     5,398 3,961
Net cash used in financing activities, discontinuing operations     (199) (1,605)
Net cash provided by financing activities     5,199 2,356
Effect of foreign exchange rates on cash and cash equivalents and restricted cash     (127) 28
Net increase (decrease) in cash and cash equivalents and restricted cash     1,986 (8,335)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH        
Beginning     511 9,891
Ending 2,497 1,556 2,497 1,556
SUPPLEMENTAL CASH FLOW DISCLOSURE        
Cash paid for interest     1,185 827
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES        
Fixed assets acquired through capital lease arrangement     145 150
Conversion of debt and accrued interest into common stock 612   350 0
Increase in fair value of conversion option     547 0
Exchanges of principal on Convertible Note for common stock     612 0
Fair value of warrants reclassified from liabilities to equity     0 426
Beneficial conversion feature on Convertible Note     0 328
Disposal of Business:        
Gain on disposal of business 8,496   8,496  
Receivables 1,082   1,082  
Other current assets 43   43  
Obligations under finance leases 0   0  
Deferred revenue 0   0  
Line of credit 0   0  
Term note 0   0  
Note receivable from IDXG (6,795)   (6,795)  
Clinical Business Disposal        
CASH FLOWS FROM INVESTING ACTIVITIES        
Net cash received in disposal     828 0
Disposal of Business:        
Goodwill 1,188 0 1,188 0
Accounts payable and accrued expenses (287) 0 (287) 0
Gain on disposal of business 1,222 0 1,222 0
Earn-Out from siParadigm (2,269) 0 (2,269) 0
Advance 974 0 974 0
BioPharma Disposal        
CASH FLOWS FROM INVESTING ACTIVITIES        
Net cash received in disposal     2,258 0
Disposal of Business:        
Goodwill 10,106 0 10,106 0
Accounts payable and accrued expenses (7,505) 0 (7,505) 0
Gain on disposal of business 7,274 0 7,274 0
Receivables 4,064 0 4,064 0
Other current assets 1,142 0 1,142 0
Fixed assets 4,121 0 4,121 0
Operating lease right-of-use assets 2,060 0 2,060 0
Patents and other intangible assets 42 0 42 0
Obligations under operating leases (2,110) 0 (2,110) 0
Obligations under finance leases (423) 0 (423) 0
Deferred revenue (1,053) 0 (1,053) 0
Line of credit (2,665) 0 (2,665) 0
Term note (6,000) 0 (6,000) 0
Note receivable from IDXG $ (6,795) $ 0 $ (6,795) $ 0

Source